Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

988744

registered interest
date	16/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Co-proxamol
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether there are plans to review guidance on the licensing and availability of co-proxamol.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	180284
answer	answer is ministerial correction date of answer 22/10/2018 answer text <p>There are currently no plans to review the licensing or availability of co-proxamol.</p><p>Co-proxamol is a combination of paracetamol and dextropropoxyphene which was licensed for the treatment of pain.</p><p>In 2004, the safety of co-proxamol was reviewed and it was concluded that the benefits of co-proxamol did not outweigh the risks of accidental overdose and death and that co-proxamol should be withdrawn from the market. All licences in the United Kingdom were cancelled by the end of 2007.</p><p>This was communicated to healthcare professionals in January 2005 with reminders in 2007 and 2011. Where possible existing patients were to be switched to alternative pain medication and no new patients should have been prescribed co-proxamol. It remains the case that co-proxamol is an item that should not be routinely dispensed in primary care following NHS England guidance.</p><p>As an unlicensed medicine, co-proxamol can be prescribed on a named patient basis if it is judged to be the most appropriate treatment by the prescribing doctor.</p><p> </p> answering member constituency West Suffolk answering member printed Matt Hancock question first answered 22/10/2018 16:50:13 answering member 4070 label Biography information for Matt Hancock
tabling member	4621 label Biography information for Darren Jones

984927

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gluten-free Foods: Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that gluten-free bread and flour is available to Coeliacs on NHS prescription.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	177784
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The Government proposed changes to the availability of gluten free (GF) foods on National Health Service prescription in its March 2017 public consultation. The majority of consultation respondents agreed with the option to restrict GF prescribing to certain foods. The Government has proposed to restrict to bread and mixes following feedback from the consultation. Evidence submitted to the consultation showed that patients generally found GF mixes easier to use and gave better results for baking GF items such as bread. Prescribing data also showed that mixes were more widely prescribed to patients than flour alone.</p><p> </p><p>This option ensures the best use of NHS resources while maintaining availability of staple GF foods for patients on prescription. Work to implement these changes is underway.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/10/2018 14:36:55 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

984930

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he plans to take to ensure that primary care providers are compensated by third party representatives for providing copies of patients' medical records where that information is gathered for purposes other than insurance underwriting.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	177785
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The implications of the General Data Protection Regulation on general practitioner practices have been raised with NHS England as part of the wider General Medical Services contract review discussions. It would not be appropriate to comment while those discussions are ongoing.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/10/2018 14:47:10 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

984933

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Cannabis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the (a) safety and (b) effectiveness of the use medical cannabis oil in the palliative care of pancreatic cancer patients who have a history of strokes.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	177786
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>Earlier this year the Chief Medical Adviser to the United Kingdom Government, Professor Dame Sally Davies, conducted a review in which she examined evidence of the medicinal benefit of cannabis based products. She found conclusive evidence of the therapeutic benefit of cannabis based medicinal products for certain medical conditions and reasonable evidence of therapeutic benefit in several other medical conditions. That review did not specifically address the safety and efficacy of cannabis oil in the palliative care of pancreatic cancer patients who have a history of strokes.</p><p> </p><p>As a result of the Chief Medical Adviser’s advice, and that of the Advisory Council on the Misuse of Drugs, the Home Office has laid legislation that means that, subject to Parliament, from 1 November certain cannabis-based products, that meet conditions related to the quality of their manufacture and supply routes, can be prescribed by doctors on the specialist register of the General Medical Council.</p><p> </p><p>The regulations do not limit the types of conditions that can be considered for treatment and specialist doctors will no longer need to seek approval from an expert panel in order for patients to access the medicines. Prescription of unlicensed cannabis-based products for medicinal use will fall within existing legal requirements and National Health Service governance arrangements for ‘special’ medicines.</p><p> </p><p>There are a number of pieces of work in train to support clinicians in making prescribing decisions. The National Institute for Health and Care Excellence will produce clinical guidance by October 2019. In the meantime, NHS England has commissioned the British Paediatric Neurology Association and the Royal College of Physicians to provide interim clinical advice to specialist doctors ahead of the regulations coming into force.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 177787 question first answered 15/10/2018 14:40:33 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

984936

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Cannabis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether medical cannabis oil will be made available for patients with pancreatic cancer that cannot be treated by other available therapies.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	177787
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>Earlier this year the Chief Medical Adviser to the United Kingdom Government, Professor Dame Sally Davies, conducted a review in which she examined evidence of the medicinal benefit of cannabis based products. She found conclusive evidence of the therapeutic benefit of cannabis based medicinal products for certain medical conditions and reasonable evidence of therapeutic benefit in several other medical conditions. That review did not specifically address the safety and efficacy of cannabis oil in the palliative care of pancreatic cancer patients who have a history of strokes.</p><p> </p><p>As a result of the Chief Medical Adviser’s advice, and that of the Advisory Council on the Misuse of Drugs, the Home Office has laid legislation that means that, subject to Parliament, from 1 November certain cannabis-based products, that meet conditions related to the quality of their manufacture and supply routes, can be prescribed by doctors on the specialist register of the General Medical Council.</p><p> </p><p>The regulations do not limit the types of conditions that can be considered for treatment and specialist doctors will no longer need to seek approval from an expert panel in order for patients to access the medicines. Prescription of unlicensed cannabis-based products for medicinal use will fall within existing legal requirements and National Health Service governance arrangements for ‘special’ medicines.</p><p> </p><p>There are a number of pieces of work in train to support clinicians in making prescribing decisions. The National Institute for Health and Care Excellence will produce clinical guidance by October 2019. In the meantime, NHS England has commissioned the British Paediatric Neurology Association and the Royal College of Physicians to provide interim clinical advice to specialist doctors ahead of the regulations coming into force.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 177786 question first answered 15/10/2018 14:40:33 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

947669

registered interest
date	24/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make it his policy to maintain the current cost-effectiveness threshold per quality-adjusted life year in the next Pharmaceutical Price Regulation Scheme.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	168184
answer	answer is ministerial correction date of answer 05/09/2018 answer text <p>The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative medicines and technologies at a price the National Health Service can afford. We have been listening to industry feedback and discussing how the medicines market is likely to evolve over the next five years. These discussions have now moved into a more formal phase and are commercially sensitive. The Government will update Parliament if and when agreement is reached.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/09/2018 10:24:43 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

947670

registered interest
date	24/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make it his policy to establish a formal mechanism to (a) involve and (b) listen to patient groups during the next Pharmaceutical Price Regulation Scheme negotiations.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	168185
answer	answer is ministerial correction date of answer 05/09/2018 answer text <p>Patient groups have made a valuable input to the development of proposals for a new medicines pricing scheme through correspondence and meetings. While the formal negotiations are confidential between industry and the Government, we will, with the Association of the British Pharmaceutical Industry, continue this dialogue as the negotiations progress.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/09/2018 10:26:55 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

938715

registered interest
date	11/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants and Benzodiazepines: Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many prescriptions of (a) individual benzodiazepine drugs and (b) individual antidepressants were dispensed in the community in 2017.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	163180
answer	answer is ministerial correction date of answer 16/07/2018 answer text <p>The information requested is shown in the following tables.</p><p><strong> </strong></p><p>Number of prescription items for individual benzodiazepine drugs written in the United Kingdom and dispensed in the community in England in 2017</p><table><tbody><tr><td><p>British National Formulary (BNF) Chemical Name</p></td><td><p>BNF Sub Paragraph Name</p></td><td><p>BNF area</p></td><td><p>Items</p></td></tr><tr><td><p>Flurazepam Hydrochloride</p></td><td><p>Hypnotics</p></td><td><p>BNF 4.1.1</p></td><td><p>1</p></td></tr><tr><td><p>Loprazolam Mesilate</p></td><td><p>Hypnotics</p></td><td><p>BNF 4.1.1</p></td><td><p>40,651</p></td></tr><tr><td><p>Lormetazepam</p></td><td><p>Hypnotics</p></td><td><p>BNF 4.1.1</p></td><td><p>22,549</p></td></tr><tr><td><p>Nitrazepam</p></td><td><p>Hypnotics</p></td><td><p>BNF 4.1.1</p></td><td><p>531,070</p></td></tr><tr><td><p>Temazepam</p></td><td><p>Hypnotics</p></td><td><p>BNF 4.1.1</p></td><td><p>1,121,685</p></td></tr><tr><td><p>Alprazolam</p></td><td><p>Anxiolytics</p></td><td><p>BNF 4.1.2</p></td><td><p>6</p></td></tr><tr><td><p>Bromazepam</p></td><td><p>Anxiolytics</p></td><td><p>BNF 4.1.2</p></td><td><p>15</p></td></tr><tr><td><p>Chlordiazepoxide Hydrochloride</p></td><td><p>Anxiolytics</p></td><td><p>BNF 4.1.2</p></td><td><p>66,477</p></td></tr><tr><td><p>Diazepam</p></td><td><p>Anxiolytics</p></td><td><p>BNF 4.1.2</p></td><td><p>5,191,486</p></td></tr><tr><td><p>Lorazepam</p></td><td><p>Anxiolytics</p></td><td><p>BNF 4.1.2</p></td><td><p>1,098,085</p></td></tr><tr><td><p>Oxazepam</p></td><td><p>Anxiolytics</p></td><td><p>BNF 4.1.2</p></td><td><p>95,596</p></td></tr><tr><td><p>Clobazam</p></td><td><p>Control Of Epilepsy</p></td><td><p>BNF 4.8.1</p></td><td><p>294,414</p></td></tr><tr><td><p>Clonazepam</p></td><td><p>Control Of Epilepsy</p></td><td><p>BNF 4.8.1</p></td><td><p>950,178</p></td></tr><tr><td><p>Clonazepam</p></td><td><p>Drugs Used In Status Epilepticus</p></td><td><p>BNF 4.8.2</p></td><td><p>170</p></td></tr><tr><td><p>Midazolam Hydrochloride</p></td><td><p>Drugs Used In Status Epilepticus</p></td><td><p>BNF 4.8.2</p></td><td><p>65,632</p></td></tr><tr><td><p>Midazolam Maleate</p></td><td><p>Drugs Used In Status Epilepticus</p></td><td><p>BNF 4.8.2</p></td><td><p>15,912</p></td></tr><tr><td><p>Midazolam Hydrochloride</p></td><td><p>Benzodiazepines</p></td><td><p>BNF 15.1.4.1</p></td><td><p>194,021</p></td></tr><tr><td><p>Total</p></td><td><p> </p></td><td><p> </p></td><td><p>9,687,948</p></td></tr></tbody></table><p>Source: Prescription Cost Analysis (PCA)</p><p> </p><p>Number of prescription items for individual antidepressants written in the United Kingdom and dispensed in the community in England in 2017</p><table><tbody><tr><td><p>BNF Chemical Name</p></td><td><p>BNF Sub Paragraph Name</p></td><td><p>BNF area</p></td><td><p>Items</p></td></tr><tr><td><p>Agomelatine</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>19,632</p></td></tr><tr><td><p>Amitriptyline Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>13,256,893</p></td></tr><tr><td><p>Amoxapine</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>4</p></td></tr><tr><td><p>Citalopram Hydrobromide</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>14,289,426</p></td></tr><tr><td><p>Citalopram Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>77,560</p></td></tr><tr><td><p>Clomipramine Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>300,358</p></td></tr><tr><td><p>Dosulepin Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>817,105</p></td></tr><tr><td><p>Doxepin</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>30,556</p></td></tr><tr><td><p>Duloxetine Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>2,040,053</p></td></tr><tr><td><p>Escitalopram</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>1,007,713</p></td></tr><tr><td><p>Fluoxetine Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>6,632,295</p></td></tr><tr><td><p>Flupentixol Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>139,723</p></td></tr><tr><td><p>Fluvoxamine Maleate</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>22,509</p></td></tr><tr><td><p>Imipramine Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>156,555</p></td></tr><tr><td><p>Isocarboxazid</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>1,653</p></td></tr><tr><td><p>Lofepramine Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>214,193</p></td></tr><tr><td><p>Mianserin Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>3,834</p></td></tr><tr><td><p>Mirtazapine</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>8,198,345</p></td></tr><tr><td><p>Moclobemide</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>18,867</p></td></tr><tr><td><p>Nefazodone Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>151</p></td></tr><tr><td><p>Nortriptyline</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>589,443</p></td></tr><tr><td><p>Other Antidepressant Preps</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>3</p></td></tr><tr><td><p>Oxitriptan</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>33</p></td></tr><tr><td><p>Paroxetine Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>1,382,209</p></td></tr><tr><td><p>Phenelzine Sulfate</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>15,341</p></td></tr><tr><td><p>Reboxetine</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>28,520</p></td></tr><tr><td><p>Sertraline Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>12,924,636</p></td></tr><tr><td><p>Tranylcypromine Sulfate</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>6,818</p></td></tr><tr><td><p>Trazodone Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>1,133,363</p></td></tr><tr><td><p>Trimipramine Maleate</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>51,824</p></td></tr><tr><td><p>Tryptophan</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>1,927</p></td></tr><tr><td><p>Venlafaxine Hydrochloride</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>4,125,810</p></td></tr><tr><td><p>Vortioxetine</p></td><td><p>Antidepressant Drugs</p></td><td><p>BNF 4.3</p></td><td><p>43,023</p></td></tr><tr><td><p>Total</p></td><td><p> </p></td><td><p> </p></td><td><p>67,530,375</p></td></tr></tbody></table><p>Source: PCA</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/07/2018 16:11:11 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

937489

registered interest
date	09/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he plans to take to ensure that primary care providers are compensated by third party representatives of patients for providing copies of those patients' medical records.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	162134
answer	answer is ministerial correction date of answer 12/07/2018 answer text <p>The European Union General Data Protection Regulation (GDPR) came into effect from 25 May, replacing the Data Protection Act 1998. Within the updated regulation is the right of access, which gives individuals the right to obtain a copy of their personal data, including, from a health perspective, copies of medical records. Previously, under the Data Protection Act 1998, organisations were able to make a charge for dealing with the administration required in such a request. Under the GDPR, the ability in law to levy such charges has been removed in most cases.</p><p> </p><p>One exception to this principle is medical information required by insurance companies for underwriting purposes. The right of access under GDPR confers more personal information than is needed or is justified for insurance underwriting. Accordingly, insurance companies should instead use the established mechanism of the Access to Medical Reports Act 1988 (AMRA) to obtain summary medical reports from general practitioners (GPs). The AMRA allows the GP to charge a reasonable fee to cover the cost of copying the report.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 12/07/2018 10:56:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4621 label Biography information for Darren Jones

900409

registered interest
date	09/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Social Services: Minimum Wage
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of (a) care homes and (b) individuals who pay directly for care who are unable to afford to pay the six-year back payment liability to carers.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	142500
answer	answer is ministerial correction date of answer 16/05/2018 answer text <p>The Department commissioned analysis to assess the impact of National Minimum Wage sleep-in liabilities across the social care sector. This work forms part of the evidence base that is being used to assess options and is subject to further analysis and refinement. Consequently, there is currently no timetable for sharing this information.</p><p> </p><p>Personal budget holders and individuals arranging their own care are often amongst the most vulnerable in society. HM Revenue and Customs are working with local authorities to ensure that personal budget holders receive the necessary help and support.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 16/05/2018 12:47:37 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4621 label Biography information for Darren Jones